AstraZeneca's Ultomiris Receives FDA Accelerated Approval for IgA Nephropathy

AstraZeneca's Alexion unit has received FDA accelerated approval for Ultomiris (ravulizumab-cwvz) to reduce proteinuria in adult patients with primary IgA nephropathy (IgAN) at risk of disease progression. This approval enhances the therapeutic applications of Ultomiris, a crucial asset for the company, and represents a significant advancement for patients with this rare kidney condition.